GenAI offers a realistic path forward in tackling previously undruggable targets, with the potential to reshape the entire ...

Isomorphic Labs raised $600 million in its first external funding round, led by Thrive Capital with participation from GV and Alphabet, according to the Financial Times. The AI-first drug design and ...

Isomorphic Labs, the AI drug-discovery platform that was spun out of Google's DeepMind in 2021, has raised external capital ...

Goldman Sachs estimates that AI drug discovery and breakthroughs like gene editing will add 0.5% to 2.5% to the U.S. gross ...

We may make money when you click on links to our partners. Learn More. AI drug design and development company Isomorphic Labs announced on Monday that it raised $600 million in its first external ...

In a major step toward more reliable AI-assisted molecular design, researchers from National Taiwan University have ...

Its deal with the US-based AI-driven drug design and development company will see Cloud design novel small-molecule agents to GSK-specified targets. Ed Addison, CEO of Cloud Pharmaceuticals ...

Google DeepMind CEO Demis Hassabis envisions AI eradicating all diseases within a decade, potentially revolutionizing drug ...

Artificial intelligence (AI)-based drug developer Isomorphic Labs said it has raised $600 million in its first external funding round, with the proceeds expected to accelerate its research and ...

New center will use cutting-edge AI to accelerate the creation of life-saving medicines AI Small Molecule Drug Discovery Center Photo 1 Left to Right: Ethan Grimes, BS, and Paul Morgan, MD, conduct ...